LLY Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$1,324.87median target· current $1,138.34 (+16.4%)30 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
6 articles · sorted by dateVia 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio38.16Forward 24.15
EPS (TTM)$29.7726.2% YoY
Profit margin33.5%HEALTHCARE
Market cap$1.01TMega cap
Valuation
- Forward P/E
- 24.15
- PEG ratio
- 1.13
- P/B
- 29.95
- P/S (TTM)
- 12.72
- EV/EBITDA
- 25.43
Profitability & growth
- ROE (TTM)
- 102.3%
- Operating margin
- 54.2%
- Revenue growth YoY
- 47.7%
- Dividend yield
- 0.6%
- Beta
- 0.50
Last earnings
Aug 5, 2026 · Estimate $6.01 · Reported $8.38
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Eli Lilly and Company
Company profileEli Lilly and Company is an American pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries.
Classification
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Exchange
- NYSE
- Country
- USA
- Currency
- USD
Company profile
- HQ
- LILLY CORPORATE CENTER, INDIANAPOLIS, IN
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$1.01T
Shares outstanding$891.7M
52W high$1,292.65
52W low$707.59
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent